Cargando…
Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma
Despite decades of research and numerous clinical trials, the prognosis of patients diagnosed with glioblastoma (GBM) remains dire with median observed survival at 8 months. There is a critical need for novel treatments for GBM, which is the most common malignant primary brain tumor. Major advances...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301268/ https://www.ncbi.nlm.nih.gov/pubmed/37375742 http://dx.doi.org/10.3390/ph16060793 |